Advertisement

Subclinical inflammation as a predictor for erectile dysfunction after brachytherapy for localized prostate cancer

      Abstract

      PURPOSE: Neutrophil-to-lymphocyte ratio (NLR), a marker for subclinical inflammation, has been previously shown to be associated with erectile dysfunction (ED). We studied the potential predictive value of the NLR on ED after prostate brachytherapy (PB) for PCa.
      METHODS AND MATERIALS: Between July 2005 and January 2021, 842 patients were included in this retrospective study of a prospectively maintained database. ED was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) physician-reported scale. ED was defined as a Grade 2 or 3 function. NLR count was determined 1–2 months before PB and separated into values PB <2 and ≥2. Patient characteristics and erectile function at last follow-up were compared for patients with a Univariate and multivariate analyses were performed to evaluate the predictive value of baseline NLR ≥2 on post-PB ED.
      RESULTS: Baseline NLR ≥2 was found to be a statistically significant predictor of post-PB ED on both univariate (p = 0.002) and multivariate analyses (p = 0.008). Furthermore, the difference in ED prevalence between the NLR <2 and NLR ≥2 groups became more pronounced with longer follow-up after PB. The ED rate at 5 years post-PB was 43% for the NLR ≥2 groups, compared to 29% for the NLR <2 groups.
      CONCLUSIONS: Subclinical systemic inflammation is a potentially important factor for predicting sexual toxicity after pelvic radiotherapy. NLR may be used as a proxy for predicting post-PB ED.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rawla P.
        Epidemiology of prostate cancer.
        World J Oncol. 2019; 10: 63
        • Klaassen Z.
        • Arora K.
        • Wilson S.N.
        • et al.
        Decreasing suicide risk among patients with prostate cancer: implications for depression, erectile dysfunction, and suicidal ideation screening.
        Urologic Oncology: Seminars and Original Investigations. Elsevier, 2018: 60-66
        • Bazinet A.
        • Zorn K.C.
        • Taussky D.
        • et al.
        Favorable preservation of erectile function after prostate brachytherapy for localized prostate cancer.
        Brachytherapy. 2020; 19: 222-227
        • Putora P.M.
        • Engeler D.
        • Haile S.R.
        • et al.
        Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients.
        Strahlentherapie und Onkologie. 2016; 192: 182-189
        • Matfin G.
        • Jawa A.
        • Fonseca V.A.
        Erectile dysfunction: interrelationship with the metabolic syndrome.
        Curr Diab Rep. 2005; 5: 64-69
        • Müller A.
        • Mulhall J.P.
        Cardiovascular disease, metabolic syndrome and erectile dysfunction.
        Curr Opin Urol. 2006; 16: 435-443
        • Vlachopoulos C.
        • Rokkas K.
        • Ioakeimidis N.
        • Stefanadis C.
        Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links.
        Eur Urol. 2007; 52: 1590-1600
        • Ventimiglia E.
        • Cazzaniga W.
        • Pederzoli F.
        • et al.
        The role of neutrophil-to-lymphocyte ratio in men with erectile dysfunction—Preliminary findings of a real-life cross-sectional study.
        Andrology. 2018; 6: 559-563
        • Aslan A.
        • Kaya Y.
        • Cirakoglu A.
        • et al.
        Neutrophil-lymphocyte ratio could be a marker for erectile dysfunction.
        Urol J. 2019; 16: 216-220
        • Yasui M.
        • Hasegawa Y.
        • Kawahara T.
        • et al.
        Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate.
        Mol Clin Oncol. 2018; 8: 587-591
        • Kawahara T.
        • Kato M.
        • Tabata K.
        • et al.
        A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
        BMC Cancer. 2020; 20: 1-8
        • Kweon O.
        • Lee M.K.
        • Kim H.J.
        • et al.
        Neutropenia and neutrophil-to-lymphocyte ratio in a healthy Korean population: race and sex should be considered.
        Int J Lab Hematol. 2016; 38: 308-318
        • Forget P.
        • Khalifa C.
        • Defour J.-.P.
        • et al.
        What is the normal value of the neutrophil-to-lymphocyte ratio?.
        BMC Res Notes. 2017; 10: 1-4
        • Sambel M.
        • Kilic M.
        • Demirbas M.
        • et al.
        Relationship between erectile dysfunction and the neutrophil to lymphocyte and platelet to lymphocyte ratios.
        Int J Impot Res. 2018; 30: 27-35
        • Demirci A.
        • Ozgur B.C.
        The effect of using tadalafil 5 mg/day on neutrophil–lymphocyte and platelet–lymphocyte ratios in mild-medium and severe erectile dysfunction patients; and comparison of clinical response.
        Andrologia. 2019; 51: e13347
        • Zagar T.M.
        • Stock R.G.
        • Cesaretti J.A.
        • Stone N.N.
        Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS.
        Brachytherapy. 2007; 6: 26-33
        • Buckstein M.
        • Carpenter T.J.
        • Stone N.N.
        • Stock R.G.
        Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up.
        Urology. 2013; 81: 364-369
        • Wortel R.C.
        • Incrocci L.
        • Mulhall J.P.
        Reporting erectile function outcomes after radiation therapy for prostate cancer: challenges in data interpretation.
        J Sex Med. 2017; 14: 1260-1269